[go: up one dir, main page]

WO2002076400A3 - Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion - Google Patents

Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion Download PDF

Info

Publication number
WO2002076400A3
WO2002076400A3 PCT/US2002/009335 US0209335W WO02076400A3 WO 2002076400 A3 WO2002076400 A3 WO 2002076400A3 US 0209335 W US0209335 W US 0209335W WO 02076400 A3 WO02076400 A3 WO 02076400A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
preventing
inflamation
inosine
reperfusion disease
Prior art date
Application number
PCT/US2002/009335
Other languages
English (en)
Other versions
WO2002076400A2 (fr
Inventor
Andrew Salzman
Csaba Szabo
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Priority to JP2002574916A priority Critical patent/JP2004525136A/ja
Priority to EP02725360A priority patent/EP1383505A4/fr
Priority to CA002441806A priority patent/CA2441806A1/fr
Publication of WO2002076400A2 publication Critical patent/WO2002076400A2/fr
Publication of WO2002076400A3 publication Critical patent/WO2002076400A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions comportant un composé d'inosine et des procédés de traitement ou de prévention d'une maladie inflammatoire ou d'une maladie de reperfusion comportant l'administration d'une quantité efficace d'un composé d'inosine à un patient qui en a besoin. FIG. 1 : A-E IDEM (RIEN A TRADUIRE) F DUREE APRES LPS (HEURES)
PCT/US2002/009335 2001-03-26 2002-03-26 Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion WO2002076400A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002574916A JP2004525136A (ja) 2001-03-26 2002-03-26 イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用
EP02725360A EP1383505A4 (fr) 2001-03-26 2002-03-26 Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion
CA002441806A CA2441806A1 (fr) 2001-03-26 2002-03-26 Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/817,829 US20010053763A1 (en) 1998-12-02 2001-03-26 Method and composition for modulating an immune response
US09/817,829 2001-03-26

Publications (2)

Publication Number Publication Date
WO2002076400A2 WO2002076400A2 (fr) 2002-10-03
WO2002076400A3 true WO2002076400A3 (fr) 2002-12-05

Family

ID=25223972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009335 WO2002076400A2 (fr) 2001-03-26 2002-03-26 Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion

Country Status (5)

Country Link
US (1) US20010053763A1 (fr)
EP (1) EP1383505A4 (fr)
JP (1) JP2004525136A (fr)
CA (1) CA2441806A1 (fr)
WO (1) WO2002076400A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20050234073A1 (en) * 2003-03-24 2005-10-20 Blumberg Richard S Methods of inhibiting inflammation
US20050090426A1 (en) * 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation
CN113398080B (zh) * 2021-06-23 2022-12-02 海南通用康力制药有限公司 一种注射用肌苷及其制备方法
WO2023132372A1 (fr) * 2022-01-07 2023-07-13 株式会社マルハチ村松 Aliment fonctionnel contenant un extrait dérivé de bonite pour la prévention ou l'amélioration des troubles neuropsychiatriques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148999C1 (ru) * 1997-05-28 2000-05-20 Санкт-Петербургская государственная медицинская академия Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс
WO2000047601A1 (fr) * 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Polynucleotides a chaine raccourcie et procede de preparation correspondant
RU2160591C1 (ru) * 1999-06-28 2000-12-20 Казанский государственный медицинский университет Способ терапии бронхиальной астмы у детей

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
DE69534745T2 (de) * 1995-04-21 2006-10-05 University Of South Florida, Tampa Immunopotenzierende 5'-nucleotidase-resistente inosinmonophosphat-derivate und ihre verwendung
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148999C1 (ru) * 1997-05-28 2000-05-20 Санкт-Петербургская государственная медицинская академия Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс
WO2000047601A1 (fr) * 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Polynucleotides a chaine raccourcie et procede de preparation correspondant
RU2160591C1 (ru) * 1999-06-28 2000-12-20 Казанский государственный медицинский университет Способ терапии бронхиальной астмы у детей

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] KAZANSKII GOSUDARSTVENNYI MEDITSINSKII UNIVERSITET; "Complex therapy with riboxin in treatment of children with bronchial asthma", XP002958113, accession no. ACS Database accession no. 2002:91703 *
DATABASE HCAPLUS [online] MATSUYAMA ET AL.: "Shortened-chain polynucleotides and process for the preparation thereof", XP002958112, accession no. ACS Database accession no. 2000:573814 *
DATABASE HCAPLUS [online] SHABROV ET AL.: "Ethymizoe application as anti-arrhytmia preparation for preventing ventricular extrasystole in myocardial ischemia patients", XP002958111, accession no. ACS Database accession no. 2001:661872 *
See also references of EP1383505A4 *

Also Published As

Publication number Publication date
US20010053763A1 (en) 2001-12-20
WO2002076400A2 (fr) 2002-10-03
EP1383505A2 (fr) 2004-01-28
EP1383505A4 (fr) 2006-08-09
CA2441806A1 (fr) 2002-10-03
JP2004525136A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2002056912A3 (fr) Methode de traitement du cancer
WO2004060882A8 (fr) Ligands des recepteurs cb 1/cb 2 et utilisation associee dans le traitement de la douleur
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
WO2005011653A3 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MXPA03005893A (es) Proteccion, restauracion, y mejora de celulas, tejidos y organos que responden a la eritropoyetina.
WO2005011655A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2001092288A3 (fr) Composes de cobalamine utilises comme agents antibiotiques et comme agents d'imagerie
WO2005030753A3 (fr) Agents therapeutiques utiles pour traiter la douleur
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
WO2001066103A3 (fr) Formulation et methode de traitement des neoplasmes par inhalation
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2002094189A3 (fr) Compositions et procedes de traitement ou de prevention de convulsions ou de crises
WO2001062235A3 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2002087503A3 (fr) Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
WO2002076400A3 (fr) Composes d'inosine et leurs utilisations pour le traitement ou la prevention d'une inflammation ou d'une maladie de reperfusion
WO2001085188A3 (fr) Utilisation d'echinacea comme agent hematinique
WO2002062334A3 (fr) Composes de chimioprevention des cancers et compositions et procedes de traitement des cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002255927

Country of ref document: AU

Ref document number: 2002574916

Country of ref document: JP

Ref document number: 2441806

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002725360

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002725360

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642